AMGEN INC

1. Executive Summary

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and markets innovative human therapeutics for serious diseases, with a focus on oncology, cardiovascular, inflammation, and bone health. Its portfolio includes blockbuster drugs like Enbrel, Prolia, and Repatha, and it has expanded into rare diseases through the acquisition of Horizon Therapeutics. Amgen leverages its expertise in biologics manufacturing and biosimilars to maintain a competitive edge.

2. Government Reliance & Contracts

Amgen’s U.S. product sales are heavily dependent on federal healthcare programs, with Medicare and Medicaid estimated to account for 35–40% of domestic revenue. The company holds multiple contracts with the Department of Veterans Affairs and the Department of Defense to supply its drugs at federally negotiated prices. During the COVID-19 pandemic, Amgen served as a contract manufacturer for Eli Lilly’s antibody therapies under Operation Warp Speed, supported by U.S. government funding. Additionally, Amgen’s products are reimbursed through Medicare Part B and Part D, making federal policy changes a significant risk factor.

3. Moats & Key Technology

Amgen’s primary moat is its extensive patent estate and manufacturing know‑how in biologics. Key patent protections include Enbrel’s U.S. exclusivity until 2029 via a settlement blocking biosimilars, and denosumab (Prolia/Xgeva) patents extending into the late 2020s. The company pioneered recombinant DNA technology and has developed advanced platforms such as BiTE (bispecific T‑cell engager) technology for immuno‑oncology and a first‑in‑class KRAS inhibitor (Lumakras). Amgen also operates a large‑scale biosimilar business, leveraging its manufacturing infrastructure to produce lower‑cost versions of complex biologics, creating a dual‑moat strategy. Its recent acquisition of Horizon adds rare disease drugs with strong orphan drug exclusivity.

4. Capital & Shadow Backers

Amgen went public in 1983 and is a component of the Dow Jones Industrial Average. The company is widely held by institutional investors; top shareholders include Vanguard Group, BlackRock, and State Street. There are no shadow backers or venture capital ties. Amgen has a long history of returning capital to shareholders through dividends and aggressive share buybacks, with a current annual dividend yield around 3%.

5. Recent Catalysts

In October 2023, Amgen completed the $27.8 billion acquisition of Horizon Therapeutics, adding fast‑growing rare disease assets like Tepezza and Krystexxa, after resolving FTC antitrust concerns. The company’s obesity candidate AMG 133 (maridebart cafraglutide) is in Phase 2 trials, with data expected in 2024, positioning Amgen in the high‑demand GLP‑1 market. Amgen launched Amjevita, the first biosimilar to Humira, in January 2023, opening a new revenue stream. The patent cliff for legacy products like Enbrel and Prolia remains a long‑term risk, but the Horizon deal and pipeline progress are key offsets. In its 2023 10‑K, Amgen reported total revenues of $28.2 billion, up 7% year‑over‑year, with Horizon contributing $1.1 billion in the fourth quarter.